. 2017 Mar 22;7:294. doi: 10.1038/s41598-017-00455-7

Table 1.

Summary of I942 and I178 activities in vitro.

Experimental Techniques	EPAC1		EPAC2
Experimental Techniques	I942	I178	I942	I178
8NBD-cAMP Competition Assays	IC₅₀ ≈ 35 μM	IC₅₀ ≈ 40 μM	IC₅₀ ≈ 35 μM	IC₅₀ ≈ 40 μM
GEF Activation (no cAMP)	AC₅₀ ≈ 50 μM	AC₅₀ ≈ 200 μM	N/A	N/A
GEF Inhibition (with cAMP)	IC₅₀ ≈ 300 μM	IC₅₀ ≈ 500 μM	IC₅₀ ≈ 110 μM	IC₅₀ ≈ 250 μM
NMR	Strong, Specific Interaction	Strong, Specific Interaction	Strong, Specific Interaction	Weak, specific interaction

The table shows the relative activities of I942 and I178 against EPAC1 and EPAC2 in NMR, CNBD binding assays (8NBD-cAMP Competition Assays) and in vitro GEF activity assays, in the presence or absence of cAMP. IC₅₀ refers to the ability of I942 and I178 to compete with 8NBD-cAMP binding to isolated CNBs or inhibit EPAC GEF activity in the presence of cAMP. AC₅₀, refers to the ability of I942 and I178 to promote EPAC GEF activity in the absence of cAMP. N/A refers to the inability of I942 and I178 to promote GEF activity of EPAC2.